Fujing Wang

Dr. Fujing Wang


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HZHaogang Zhang
Haogang Zhang
RJRuichun Jia
Ruichun Jia
CWChunjing Wang
Chunjing Wang
THTianming Hu
Tianming Hu
FWFujing Wang
Fujing Wang

5 May 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ZWZhiyu Wang
Zhiyu Wang
ZZZhuoqi Zhang
Zhuoqi Zhang
KZKe Zhang
Ke Zhang
QZQiaoxia Zhou
Qiaoxia Zhou
SCSidong Chen
Sidong Chen
SLShenglong Li
Shenglong Li
Background: Glycerolipid metabolism is involved in the genesis and progression of colon cancer. The current study aims at exploring the prognostic value and potential molecular mechanism of glycerolipid metabolism-related genes in colon cancer from the perspective of multi-omics.Methods: Clinical information and mRNA expression data of patients with colon cancer were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Single-sample gene set enrichment analysis (ssGSEA) was applied to calculate the glycerolipid metabolism-related gene enrichment score (GLMS). Univariable and multivariable Cox regression analyses were used to study the prognostic value of GLMS in TCGA-COAD and GSE39582 cohorts. The molecular mechanism of the prognostic factor was investigated via immune cell infiltration estimation and correlation analysis of cancer hallmark pathways. Single-cell transcriptomic dataset GSE146771 was used to identify the cell populations which glycerolipid metabolism targeted on.Results: The GLMS was found to be associated with tumor location and consensus molecular types (CMSs) of colon cancer in TCGA-COAD cohort (P < 0.05). Patients in the low-GLMS group exhibited poorer overall survival (OS) in TCGA cohort (P = 0.03; HR, 0.63; 95% CI, 0.42–0.94), which was further validated in the GSE39582 dataset (P < 0.001; HR, 0.57; 95% CI, 0.43–0.76). The association between the GLMS and OS remained significant in the multivariable analysis (TCGA cohort: P = 0.04; HR, 0.64; 95% CI, 0.42–0.98; GSE39582 cohort: P < 0.001; HR, 0.60; 95% CI, 0.45–0.80). The GLMS was positively correlated with cancer hallmark pathways including bile acid metabolism, xenobiotic metabolism, and peroxisome and negatively correlated with pathways such as interferon gamma response, allograft rejection, apoptosis, and inflammatory response (P < 0.05). Increased immune infiltration and upregulated expression of immune checkpoints were observed in patients with lower GLMS (P < 0.05). Single-cell datasets verified the different distribution of GLMS in cell subsets, with significant enrichment of GLMS in malignant cells and Tprolif cells.Conclusion: We demonstrated that GLMS was a potential independent prognostic factor for colon cancer. The GLMS was also correlated with several cancer hallmark pathways, as well as immune microenvironment.

7 August 2018 in Oncology Reports
Verified
Journal Article
Open access
PDF file
PQPengfei Qiao
Pengfei Qiao
SLShenglong Li
Shenglong Li
HZHaogang Zhang
Haogang Zhang
LYLei Yao
Lei Yao
FWFujing Wang
Fujing Wang
Colorectal cancer (CRC) is among the most common malignancies of the digestive system. Dysregulation of miRNAs and the farnesoid X receptor (FXR) are involved in the progression of CRC. In the present study, the effects of FXR and miR‑135A1 in CRC were evaluated. Reverse transcription quantitative‑polymerase chain reaction (RT‑qPCR) was used to examine the expression of miR‑135A1 in patient CRC tissues and adjacent non‑tumor tissues, as well as cell lines. The association between miR‑135A1 and clinical characteristics of patients with CRC was also investigated. RT‑qPCR and western blotting were used to evaluate the expression of miR‑135A1 targets. Regulation of cyclin G2 (CCNG2) by miR‑135A1was confirmed using luciferase assays. The biological effects of miR‑135A1 were assessed in transfected and untransfected CRC cell lines using colony formation assays, cell‑cycle analysis by flow cytometry, and CCK‑8 assays. miR‑135A1 was upregulated in CRC specimens and cell lines. miR‑135A1 expression was strongly associated with poor cell differentiation, high expression of carbohydrate antigen (CA)125, CA199, carcinoembryonic antigen and survival rate of patients with CRC. Expression of CCNG2 was downregulated in CRC patients and cell lines, and was further demonstrated to be among the downstream targets of miR‑135A1. The present study indicated that inhibition of miR‑135A1 expression leads to cell cycle arrest and inhibition of proliferation of CRC cells via increasing CCNG2 expression. In the present study, activation of FXR by GW4064 increased CCNG2 expression via suppression of miR‑135A1 expression, and the FXR/miR‑135A1/CCNG2 axis was demonstrated to be involved in mediating cell proliferation. In conclusion, activation of FXR by GW4064 suppresses cell proliferation and causes cell cycle arrest in CRC, and the miR‑135A1/CCNG2 pathway was suggested to be involved in this step.

1 October 2015 in Medicine
Verified
Journal Article
Open access
YKYue Kang
Yue Kang
SLShenglong Li
Shenglong Li
QGQinghong Ge
Qinghong Ge
XLXinran Liu
Xinran Liu
ZYZhenyu Yang
Zhenyu Yang
FWFujing Wang
Fujing Wang
To investigate whether the width of gastric serosal lesions in advanced gastric cancer patients have a predictive value for peritoneal recurrence and the 5-year survival rate. A total of 1109 patients with advanced noncardia primary gastric adenocarcinoma, who underwent curative gastrectomy between January 1997 and December 2007, were included. Data about tumor size, longitudinal tumor location, resection type, serum albumin concentration, lymphatic/venous invasion, lymph node metastasis status, lesion size, histological and Borrmann type of tumor, as well as the recurrence rate and width of the gastric serosal lesions were collected and analyzed. The peritoneal recurrence rate in patients with gastric serosal lesions ≤3 cm was lower than in patients with gastric serosal lesions >3 cm. Multivariate analyses of the 5-year survival rate variables for all patients revealed significant correlations with serum albumin concentrations (HR 1.382, P = 0.002, 95% CI 1.123–1.701), width of serosa changes (HR 1.377, P = 0.020, 95% CI 1.053–1.802), depth of invasion (HR 1.529, P < 0.001, 95% CI 1.288–1.814), and lymph node metastasis (HR 1.551, P < 0.001, 95% CI 1.420–1.694), whereas for recurrent patients only serum albumin concentrations (HR 2.000, P < 0.001, 95% CI 1.425–2.805), width of serosa changes (HR 1.867, P = 0.002, 95% CI 1.248–2.793), and lymph node metastasis (HR 1.521, P < 0.001, 95% CI 1.249–1.852) correlated with the 5-year survival rate. Gastric serosal lesions >3 cm may indicate a high risk for peritoneal recurrence and serve as additional indicators for preventive postoperative adjuvant chemotherapies in patients with advanced gastric cancer.

30 September 2023 in Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
SLShenglong Li
Shenglong Li
HZHao Zheng
Hao Zheng
QGQinghong Ge
Qinghong Ge
SXShuli Xia
Shuli Xia
KZKe Zhang
Ke Zhang
FWFujing Wang
Fujing Wang
Shenglong Li, Hao Zheng, Qinghong Ge, Shuli Xia, Ke Zhang, Chunjing Wang, Fujing Wang. J Cancer Prev 2023;28:106-14. https://doi.org/10.15430/JCP.2023.28.3.106

25 March 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
MWMingyu Wang
Mingyu Wang
JWJiayi Wang
Jiayi Wang
XWXinyi Wang
Xinyi Wang
JLJian Li
Jian Li
YHYingjia Hu
Yingjia Hu
FWFujing Wang
Fujing Wang
Background and objectives: Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide and has a poor prognosis. Novel biomarkers are required to predict the survival of patients with this aggressive disease. Although the pan-immune-inflammation value (PIV) has been associated with outcomes in various malignancies, its prognostic role in GC remains unclear. Materials and methods: Clinical data of 793 patients with pT2-4 GC were retrospectively reviewed and analyzed. An optimal cutoff value was determined using receiver operating characteristic (ROC) curve analysis to stratify patients into high- and low-PIV groups. The prognostic performances of PIV and other immune-inflammatory biomarkers (IIBs) were compared using ROC analysis. Associations between the PIV and clinicopathological characteristics were also assessed. Kaplan–Meier survival curves were constructed for progression-free survival (PFS) and overall survival (OS). Univariate and multivariate Cox regression analyses were performed to determine independent prognostic factors. Results: The PIV demonstrated superior predictive value for survival compared to other peripheral blood-derived markers. High PIV values were significantly correlated with the Helicobacter pylori infection status, a larger tumor size, and an advanced TNM stage. Patients in the high-PIV group, particularly those with stages III and IV disease, had significantly worse PFS and OS. In multivariate analysis, the PIV remained an independent prognostic factor for survival outcomes in patients with pT2-4 GC. Conclusion: This study established PIV as a significant and independent prognostic biomarker for pT2-4 GC. PIV exhibits a more sensitive predictive ability for the tumor burden and systemic inflammation than other evaluated IIBs, which provides potential clinical value for patients with pT2-4 GC.